Quanterix Corp — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 68/100
What the filing says
Q2 2026 revenue came in at $32.9M (up 34% YoY but below expectations); the company slashed full-year 2026 guidance from $169–174M to $142–148M (down 15–16%), citing execution challenges and market softness. The company also took a $26.9M goodwill impairment on the Akoya acquisition, pushed cash-flow breakeven from H2 2026 to 2027, and expects year-end cash of ~$80M instead of $100M. Management appointed a new Chief Commercial Officer (Jim Gute, ex-Exact Sciences), plus COO, CFO, and diagnostics head.
Why this rating
Major revenue guidance cut (15–16%), material impairment, and breakeven delay are significant relative to ~$239M market cap. Execution missteps and weakening end-markets threaten near-term profitability trajectory.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.